Advances in Research on Immune Checkpoint Inhibitors and Related Colitis
10.3969/j.issn.1008-7125.2020.01.011
- Author:
Yadan ZHENG
1
Author Information
1. Department of Gastroenterology, First Affiliated Hospital of Soochow University
- Publication Type:Journal Article
- Keywords:
Adverse Drug Reaction;
Colitis;
Diarrhea;
Immune Checkpoint Inhibitors
- From:Chinese Journal of Gastroenterology
2020;25(1):51-54
- CountryChina
- Language:Chinese
-
Abstract:
Immunotherapy, as a new method to inhibit tumor growth, has attracted wide attention. Immune checkpoint inhibitors (ICIs) enhance the ability of T cells to recognize and kill tumor cells by inhibiting the activity of cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and programmed death/ligand 1 (PD-1/PD-L1). Since immune checkpoints (CTLA-4, PD-1/PD-L1) play a crucial role in regulating the body's tolerance to its own antigen, ICIs may cause the loss of normal tolerance of body structure and leading to immune-related adverse effects (irAEs). Colitis is one of the common irAEs. This article reviewed advances in research on incidence, symptoms, diagnosis, risk factors, pathogenesis and treatment of ICIs-related colitis.
